<?xml version="1.0" encoding="UTF-8"?>
<table-wrap id="Tab3">
 <label>Table 3</label>
 <caption>
  <p>Transcripts validated in adalimumab good-responders by real-time quantitative polymerase chain reaction (RT-QPCR)</p>
 </caption>
 <table frame="hsides" rules="groups">
  <thead>
   <tr>
    <th>Rank</th>
    <th>Target name</th>
    <th>Gene</th>
    <th>Rq</th>
    <th>Rq min</th>
    <th>Rq max</th>
    <th>Adjusted 
     <italic>p</italic> value
    </th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td>1</td>
    <td>Hs00190574_m1</td>
    <td>
     <italic>LIN7A</italic>
    </td>
    <td>0.69</td>
    <td>0.59</td>
    <td>0.8</td>
    <td>0.01</td>
   </tr>
   <tr>
    <td>2</td>
    <td>Hs00191719_m1</td>
    <td>
     <italic>CREB5</italic>
    </td>
    <td>0.62</td>
    <td>0.51</td>
    <td>0.76</td>
    <td>0.014</td>
   </tr>
   <tr>
    <td>3</td>
    <td>Hs00969559_m1</td>
    <td>
     <italic>ENTPD1</italic>
    </td>
    <td>0.79</td>
    <td>0.71</td>
    <td>0.88</td>
    <td>0.019</td>
   </tr>
   <tr>
    <td>4</td>
    <td>Hs01565750_m1</td>
    <td>
     <italic>ITGB7</italic>
    </td>
    <td>1.51</td>
    <td>1.25</td>
    <td>1.82</td>
    <td>0.02</td>
   </tr>
   <tr>
    <td>5</td>
    <td>Hs00185435_m1</td>
    <td>
     <italic>HLA-DMA</italic>
    </td>
    <td>1.34</td>
    <td>1.17</td>
    <td>1.52</td>
    <td>0.023</td>
   </tr>
   <tr>
    <td>6</td>
    <td>Hs01075666_m1</td>
    <td>
     <italic>IL6R</italic>
    </td>
    <td>0.76</td>
    <td>0.67</td>
    <td>0.87</td>
    <td>0.023</td>
   </tr>
   <tr>
    <td>7</td>
    <td>Hs01062258_m1</td>
    <td>
     <italic>SLC8A1</italic>
    </td>
    <td>0.68</td>
    <td>0.59</td>
    <td>0.79</td>
    <td>0.025</td>
   </tr>
   <tr>
    <td>8</td>
    <td>Hs01555410_m1</td>
    <td>
     <italic>IL1B</italic>
    </td>
    <td>0.65</td>
    <td>0.52</td>
    <td>0.82</td>
    <td>0.027</td>
   </tr>
   <tr>
    <td>9</td>
    <td>Hs00157950_m1</td>
    <td>
     <italic>HLA-DOB</italic>
    </td>
    <td>1.98</td>
    <td>1.5</td>
    <td>2.61</td>
    <td>0.03</td>
   </tr>
   <tr>
    <td>10</td>
    <td>Hs01090216_m1</td>
    <td>
     <italic>MGAM</italic>
    </td>
    <td>0.56</td>
    <td>0.41</td>
    <td>0.76</td>
    <td>0.03</td>
   </tr>
   <tr>
    <td>11</td>
    <td>Hs01072219_m1</td>
    <td>
     <italic>TRAF5</italic>
    </td>
    <td>1.47</td>
    <td>1.27</td>
    <td>1.69</td>
    <td>0.031</td>
   </tr>
   <tr>
    <td>12</td>
    <td>Hs00171280_m1</td>
    <td>
     <italic>AES</italic>
    </td>
    <td>1.4</td>
    <td>1.24</td>
    <td>1.59</td>
    <td>0.032</td>
   </tr>
   <tr>
    <td>13</td>
    <td>Hs00231092_m1</td>
    <td>
     <italic>E2F5</italic>
    </td>
    <td>1.61</td>
    <td>1.26</td>
    <td>2.07</td>
    <td>0.035</td>
   </tr>
   <tr>
    <td>14</td>
    <td>Hs00207105_m1</td>
    <td>
     <italic>ZFYVE16</italic>
    </td>
    <td>0.8</td>
    <td>0.71</td>
    <td>0.9</td>
    <td>0.037</td>
   </tr>
   <tr>
    <td>15</td>
    <td>Hs01109372_g1</td>
    <td>
     <italic>HLA-DOA</italic>
    </td>
    <td>1.63</td>
    <td>1.3</td>
    <td>2.03</td>
    <td>0.037</td>
   </tr>
   <tr>
    <td>16</td>
    <td>Hs00152972_m1</td>
    <td>
     <italic>TLR8</italic>
    </td>
    <td>0.68</td>
    <td>0.55</td>
    <td>0.83</td>
    <td>0.041</td>
   </tr>
   <tr>
    <td>17</td>
    <td>Hs00201585_m1</td>
    <td>
     <italic>STAP1</italic>
    </td>
    <td>1.51</td>
    <td>1.22</td>
    <td>1.86</td>
    <td>0.042</td>
   </tr>
  </tbody>
 </table>
 <table-wrap-foot>
  <p>The relative quantification (Rq) values are equivalent to linear fold changes for each transcript defined as the inverse log2 of the change in relative cycle threshold (∆∆Crt) values between pre-treatment and 3 months. Minimum and maximum RQ values and 
   <italic>p</italic> value are presented for each transcript along with 
   <italic>p</italic> values adjusted for multiple tests. Transcripts with an Rq value below 1 exhibited reduced expression at 3 months compared to pre-treatment. Transcripts with an Rq value above 1 exhibited increased expression at 3 months compared to pre-treatment
  </p>
 </table-wrap-foot>
</table-wrap>
